Combination therapy in hypertension: An update
S Kalra, B Kalra, N Agrawal - Diabetology & metabolic syndrome, 2010 - Springer
Meticulous control of blood pressure is required in patients with hypertension to produce the
maximum reduction in clinical cardiovascular end points, especially in patients with …
maximum reduction in clinical cardiovascular end points, especially in patients with …
Atorvastatin calcium plus amlodipine for the treatment of hypertension
A Delgado-Montero, JL Zamorano - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Hypertension (HTN) and dyslipemia (DYL) are two of the major modifiable
cardiovascular (CV) risk factors, determinants in the development of cerebrovascular and …
cardiovascular (CV) risk factors, determinants in the development of cerebrovascular and …
Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic …
TJ Dennison, JC Smith, RK Badhan… - Drug design …, 2017 - Taylor & Francis
Cardiovascular disease (CVD) is the leading cause of death among men and women
worldwide. In CVD, hypertension and dyslipidemia commonly coexist and are managed …
worldwide. In CVD, hypertension and dyslipidemia commonly coexist and are managed …
Decision-making tree for improving selectivity and sensitivity of sweeping-MEKC determination of hydrophobic analytes: Application to five cardiovascular drugs with …
MI El-Awady, S Abdel‑Razeq, S Barghash, F Belal - Microchemical Journal, 2022 - Elsevier
Efficient separation of five cardiovascular drugs has been achieved by a new micellar
electrokinetic chromatographic method based on using a general strategy that can be …
electrokinetic chromatographic method based on using a general strategy that can be …
Effect of oral atorvastatin on CD4+ CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before …
D Zhang, S Wang, Y Guan, L Wang, W Xie… - Journal of …, 2011 - journals.lww.com
Objective: Our objective was to explore the effects of atorvastatin on changes of CD4+
CD25+ regulatory T cells (Tregs), FoxP3 expression in the infarct-related coronary artery …
CD25+ regulatory T cells (Tregs), FoxP3 expression in the infarct-related coronary artery …
苯磺酸氨氯地平/阿托伐他汀钙复合制剂治疗高血压病合并高脂血症的有效性和安全性
齐丽彤， 孙跃民， 李树仁， 袁洪， 李俊峡， 钟国强… - 中国新药杂志, 2013 - cqvip.com
目的: 评价苯磺酸氨氯地平/阿托伐他汀钙片治疗高血压病合并高脂血症的有效性和安全性. 方法:
采用多中心, 随机双盲, 平行对照试验, 选取临床确诊患原发性高血压病合并原发性高脂血症的 …
采用多中心, 随机双盲, 平行对照试验, 选取临床确诊患原发性高血压病合并原发性高脂血症的 …
[PDF][PDF] Комбинация амлодипина и аторвастатина в снижении риска кардиоваскулярных осложнений
Д Дедов, Н Мукаилов, И Евтюхин - Врач, 2013 - pharmaco.rusvrach.ru
Рассматриваются вопросы применения фиксированной комбинации амлодипин/
аторвастатин у больных артериальной гипертензией и ишемической болезнью сердца …
аторвастатин у больных артериальной гипертензией и ишемической болезнью сердца …
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study
Y Nishida, Y Takahashi, T Nakayama, M Soma… - Cardiovascular …, 2011 - Springer
Background Angiotensin II receptor blockers (ARBs), including olmesartan and candesartan,
are widely used antihypertensive agents. Many clinical studies have demonstrated that …
are widely used antihypertensive agents. Many clinical studies have demonstrated that …
Cardiovascular self‐management support program for preventing cardiovascular complication behaviors and clinical outcomes in the elderly with poorly controlled …
Aim The aim of the study was to determine the feasibility, and to evaluate the effect of, a
cardiovascular self‐management support program by applying the 5A's self‐management …
cardiovascular self‐management support program by applying the 5A's self‐management …
Novel microwell-based spectrophotometric assay for determination of atorvastatin calcium in its pharmaceutical formulations
TA Wani, NY Khalil, HM Abdel-Rahman… - Chemistry Central …, 2011 - Springer
The formation of a colored charge-transfer (CT) complex between atorvastatin calcium (ATR-
Ca) as a n-electron donor and 2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinone (DDQ) as a π …
Ca) as a n-electron donor and 2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinone (DDQ) as a π …